GleamWall
中文EN

KNSA Kiniksa Pharmaceuticals International, plc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1730430 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY58.2%
TTM net income YoY205.1%
TTM EPS YoY193.3%
Revenue 3-yr CAGR56.1%
Net income 3-yr CAGR—

Margins

Gross margin90.2%
Operating margin13.8%
Net margin11.6%
FCF margin20.8%
EBITDA margin13.9%

Returns

ROE17.6%
ROA12.9%
ROIC (approx.)19.8%
Asset turnover1.12x

Leverage & solvency

Liabilities / assets27.8%
Debt / equity0.00x
Current ratio3.91x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.81x
Accruals ratio-10.5%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$285.97M$243.60M$214.27M$202.13M$180.85M$156.80M$137.78M$122.54M
Cost of revenue$27.76M$23.57M$20.80M$20.95M$20.26M$18.60M$17.87M$17.90M
Gross profit$258.21M$220.03M$193.47M$181.18M$160.60M$138.19M$119.92M$104.64M
R&D expense$32.79M$40.90M$27.48M$34.61M$24.17M$18.75M$19.32M$35.22M
SG&A expense$65.36M$63.87M$61.15M$56.77M$49.10M$46.86M$43.53M$40.53M
Operating income$54.24M$27.19M$29.27M$19.77M$24.02M$20.16M$13.27M-$19.30M
Pretax income$59.06M$31.14M$32.68M$23.27M$27.16M$22.88M$15.56M-$16.98M
Income tax$11.71M$5.71M$10.09M$9.07M$8.72M$5.04M$7.03M-$8.09M
Net income$47.34M$25.43M$22.59M$14.20M$18.43M$17.83M$8.54M-$8.89M
EBITDA$54.42M$27.36M$29.73M$20.23M$24.05M$20.17M$13.62M-$18.90M
EPS (basic)0.610.330.30—0.250.240.12—
EPS (diluted)0.560.300.27—0.230.230.11—
Weighted avg. shares (diluted)84.92M83.40M82.41M—80.04M77.94M76.15M—
Balance sheet
Cash & equivalents$81.66M$175.68M$189.95M$165.60M$174.86M$192.04M$157.13M$183.58M
Short-term investments$487.10M$350.25M$278.14M$248.48M$177.24M$115.75M$111.21M$60.05M
Receivables$30.78M$23.49M$23.22M$15.59M$51.74M$31.91M$40.06M$41.72M
Inventory$108.03M$70.93M$73.14M$54.90M$41.40M$48.18M$22.07M$26.36M
Current assets$750.10M$668.63M$594.17M$527.18M$475.53M$420.31M$355.91M$331.80M
PP&E, net$2.46M$2.58M$1.99M$1.94M$1.66M$1.08M$606,000$662,000
Intangibles$14.50M$14.75M$15.00M$15.25M$15.50M$15.75M$16.00M$16.25M
Total assets$983.24M$896.11M$825.28M$763.63M$712.33M$661.15M$599.33M$580.55M
Current liabilities$191.85M$171.25M$156.61M$139.18M$123.59M$117.83M$97.27M$100.62M
Total liabilities$273.05M$241.96M$219.59M$196.03M$176.95M$166.14M$141.84M$142.12M
Shareholders' equity$710.19M$654.15M$605.69M$567.61M$535.38M$495.01M$457.49M$438.44M
Cash flow statement
Operating cash flow$47.55M$47.20M$50.20M$53.89M$33.68M$28.09M$22.32M$18.77M
Capital expenditure$180,000$663,000$161,000$633,000$671,000$165,000$99,000$193,000
Free cash flow$47.37M$46.53M$50.04M$53.26M$33.01M$27.93M$22.23M$18.58M
Investing cash flow-$138.56M-$73.58M-$31.92M-$70.81M-$62.76M-$3.88M-$51.54M$65.29M
Financing cash flow-$3.00M$12.11M$6.07M$7.66M$11.90M$10.70M$2.77M$2.14M
Depreciation & amortization$181,000$165,000$468,000$467,000$27,000$13,000$345,000$400,000
Stock-based compensation$13.06M$11.64M$10.06M$10.23M$10.14M$8.88M$7.75M$8.30M

Free plan shows the latest 8 periods; Pro shows all 38 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.